Adrian Rawcliffe - 01 Sep 2022 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Signature
/s/ Adrian George Rawcliffe
Issuer symbol
ADAP
Transactions as of
01 Sep 2022
Net transactions value
-$4,993
Form type
4
Filing time
01 Sep 2022, 21:00:56 UTC
Previous filing
17 Aug 2022
Next filing
04 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADAP American Depositary Shares representing Ordinary Shares Sale $4,993 -2,536 -43% $1.97 3,316 01 Sep 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F2 The price reported in Column 4 is the sale price per ADS.
F3 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 89,625 ADSs and RSU-style options and other options covering an aggregate of 21,697,500 ordinary shares of the Issuer.